Methods: Patients considered for study inclusion were > 18 years old, had at least one positive blood culture for SM between January 2004 and October 2014, hospitalized at Northwestern Memorial Hospital, and treated with at least 48 hours of FQ or S/T monotherapy. Baseline demographic variables including treatment used were assessed to determine their impact on clinical outcomes. Stepwise multivariate regression was performed to assess predictors of mortality.
Results: 54 patients were included in the analysis (n= 22 FQ [levofloxacin n=4, moxifloxacin n=6, ciprofloxacin n=11] and n=32 S/T). Baseline characteristics were similar between treatment groups. Mortality rates between FQ and S/T differed numerically but not statistically (n=3, 13.6% [n=3 moxifloxacin and n=0 for levofloxacin and ciprofloxacin] and n=10, 31.3% respectively, p=0.20). Time to death from positive culture also differed numerically between treatment groups (FQ n=3 days, IQR 11-64; S/T n=12.5 days, IQR 12-36; p=0.61). Bivariate analysis revealed modified APACHE II, septic shock, mechanical ventilation, organ dysfunction, broad spectrum antibiotics prior to culture, and concomitant positive respiratory cultures with SM as positive predictors of mortality (p<0.05 for all). In a multivariate analysis, modified APACHE II score (OR 1.4, 95% CI 1.1-1.8) and broad spectrum antibiotics prior to culture (OR 8, 95% CI 1.3-49.8) remained as significant predictors of mortality.
Conclusion: FQ treated patients showed similar clinical outcomes to those treated with S/T for SM BSI. Multivariate analyses indicated that factors other than treatment had an impact on clinical outcomes. Further study is required.
M. Postelnick, None
A. Aguirre, None
M. Mclaughlin, BioCryst Pharmaceuticals: Served on Advisory Board , Consulting fee